Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature. (Record no. 5107)

MARC details
000 -LEADER
fixed length control field 03467nam a22005417a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 200709s20202020 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 0959-8049
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.1016/j.ejca.2020.03.015 [doi]
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code S0959-8049(20)30156-8 [pii]
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 32375103
245 ## - TITLE STATEMENT
Title Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature.
251 ## - Source
Source European Journal of Cancer. 132:168-175, 2020 06.
252 ## - Abbreviated Source
Abbreviated source Eur J Cancer. 132:168-175, 2020 06.
252 ## - Abbreviated Source
Former abbreviated source Eur J Cancer. 132:168-175, 2020 Jun.
253 ## - Journal Name
Journal name European journal of cancer (Oxford, England : 1990)
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2020
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2020
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Publication status ppublish
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Publication status ppublish
266 ## - Date added to catalog
Date added to catalog 2020-07-09
268 ## - Previous citation
-- European Journal of Cancer. 132:168-175, 2020 Jun.
520 ## - SUMMARY, ETC.
Abstract BACKGROUND: An amassing body of evidence exists to support an association between the use of immune checkpoint inhibitors (ICIs) and the development of tuberculosis (TB).
520 ## - SUMMARY, ETC.
Abstract CONCLUSION: Findings from our systematic review indicate that PD-(L)1 inhibitors are linked to TB reactivation. TB activation can occur in various organs and TB-related fatalities have been reported. TB screening before starting immunotherapy should be considered in high-risk patient populations. Further research, including prospective studies with patients whose baseline TB status is known, is necessary to better understand the incidence of TB reactivation during ICI therapy and how best to manage TB that develops during immunotherapy. Copyright (c) 2020 Elsevier Ltd. All rights reserved.
520 ## - SUMMARY, ETC.
Abstract METHODS: We performed a systematic review of the literature to assess the nature of this relationship using PubMed, EMBASE and meeting proceedings.
520 ## - SUMMARY, ETC.
Abstract RESULTS: We have identified 16 patients who developed active TB during immunotherapy. Median age was 61 (range: 49-87). Twelve (75%) were male and 4 (25%) were female. Lung cancer was the most common type of cancer (n = 8), followed by melanoma (n = 3) and head and neck cancer (n = 3). Median time to TB reactivation after initiation of ICI therapy was 6.3 months (range: 1-24 months). Two (13%) patients died of complications of TB (spinal cord compression, GI perforation). TB reactivation in organs (pericardium, bone, liver, and GI track; one each) other than the lungs has been documented. We did not find any cases of TB reactivation that occurred during anti-CTLA-4 therapy.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Antineoplastic Agents, Immunological/ae [Adverse Effects]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Neoplasms/dt [Drug Therapy]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Tuberculosis/ci [Chemically Induced]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged, 80 and over
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Female
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Male
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Middle Aged
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Neoplasms/pa [Pathology]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Prognosis
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Survival Rate
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Tuberculosis/pa [Pathology]
656 ## - INDEX TERM--OCCUPATION
Department MedStar Georgetown University Hospital Residents
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Zaemes, Jacob
790 ## - Authors
All authors Kim C, Zaemes J
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1016/j.ejca.2020.03.015">https://dx.doi.org/10.1016/j.ejca.2020.03.015</a>
Public note https://dx.doi.org/10.1016/j.ejca.2020.03.015
-- https://dx.doi.org/10.1016/j.ejca.2020.03.015
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1016/j.ejca.2020.03.015">https://dx.doi.org/10.1016/j.ejca.2020.03.015</a>
Public note https://dx.doi.org/10.1016/j.ejca.2020.03.015
-- https://dx.doi.org/10.1016/j.ejca.2020.03.015
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 07/09/2020   32375103 32375103 07/09/2020 07/09/2020 Journal Article

Powered by Koha